Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 2:52 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3001–3024 of 4,253 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Essential Hypertension
Interventions: LCI699, Eplerenone, LCI699-matching Placebo, Eplerenone-matching Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Safety
Interventions: PEP (Purified Exosome Product); Drug
Lead sponsor: Clinical Testing of Beverly Hills; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Encino, California

Conditions: Digital Acuity Product
Interventions: Visibly Digital Acuity Product; Device
Lead sponsor: Visibly; Industry
Eligibility: 22 Years to 40 Years
Enrollment: 358 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Andover, Massachusetts • Shelby, North Carolina • Memphis, Tennessee

Conditions: Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions: Vadadustat, Darbepoetin alfa; Drug
Lead sponsor: Akebia Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 3,554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 127
States / cities: Huntsville, Alabama • Mesa, Arizona • Pine Bluff, Arkansas + 95 more

Conditions: Nasal Congestion Associated With the Common Cold
Interventions: pseudoephedrine hydrochloride 30 mg tablets, Placebo tablets; Drug
Lead sponsor: Perrigo Company; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 565 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 11
States / cities: Anaheim, California • Costa Mesa, California • Boise, Idaho + 8 more

Conditions: Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease, Amyotrophic Lateral Sclerosis (ALS)
Interventions: Not listed
Lead sponsor: Sanguine Biosciences; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Sherman Oaks, California

Conditions: Atopic Dermatitis
Interventions: 0416, Vehicle of 0416 test product, tacrolimus ointment 0.1%; Drug
Lead sponsor: Fougera Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 793 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Melville, New York

Conditions: Visual Acuity
Interventions: senofilcon A C3, Dailies Total 1 Multifocal Contact Lenses; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 9
States / cities: Jacksonville, Florida • Longwood, Florida • Roswell, Georgia + 6 more

Conditions: Asthma
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 65
States / cities: Bakersfield, California • Huntington Beach, California • La Mesa, California + 61 more

Conditions: Migraine
Interventions: Magnesium, Placebo; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Oak Lawn, Illinois

Conditions: Urinary Bladder, Overactive
Interventions: Solifenacin Succinate Suspension, Placebo, Urotherapy; Drug · Behavioral
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Shreveport, Louisiana • Albany, New York

Conditions: Alzheimer's Disease, Dementia
Interventions: Drug: EVP-6124, Placebo; Drug
Lead sponsor: FORUM Pharmaceuticals Inc; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 42
States / cities: Tucson, Arizona • Little Rock, Arkansas • Culver City, California + 39 more

Conditions: Healthy Subjects
Interventions: Venlafaxine, Moxifloxacin, Drug - placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Tuberculosis
Interventions: Higher-Dose Rifampin; Drug
Lead sponsor: Harvard University Faculty of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Menopause, Hot Flashes
Interventions: Shatavari (Asparagus racemosus) Extract, Placebo; Dietary Supplement · Other
Lead sponsor: India Glycols Ltd; Industry
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Port Richey, Florida

Conditions: Lung Transplant
Interventions: Extended-Release Tacrolimus, Immediate-Release Tacrolimus; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 18 Years and older
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Gut Microbiome
Interventions: Dietary MACs, Control; Dietary Supplement · Other
Lead sponsor: Access Business Group; Industry
Eligibility: 40 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Cognitive Functioning
Interventions: AlphaBrain; Dietary Supplement
Lead sponsor: Onnits Labs, LLC; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Conditions: AV Fistula
Interventions: Vorapaxar sulfate, Placebo; Drug
Lead sponsor: Ken Mahaffey; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Safety and Tolerability in Healthy Volunteers
Interventions: VLX-1005, Placebo; Drug
Lead sponsor: Veralox Therapeutics; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Rosacea
Interventions: Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel, Placebo gel; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Stanford, California • Boston, Massachusetts

Conditions: Heart Failure, Overactive Bladder, Incontinence
Interventions: Extended release torsemide, Immediate release torsemide, Extended release torsemide placebo, Immediate release torsemide placebo; Drug
Lead sponsor: Sarfez Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Malignant Head and Neck Neoplasm, Mucositis, Radiation-Induced Disorder
Interventions: Educational Intervention, Gabapentin, Pain Therapy, Quality-of-Life Assessment, Questionnaire Administration, Oxycodone/Acetaminophen, Hydrocodone/Acetaminophen, Fentanyl, Ibuprofen, Magic Mouthwash; Other · Drug
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 21 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension

Purified Exosome Product (PEP) Injected Into the Hypodermis

Prospective, Randomized, Controlled Agreement and Reproducibility Clinical Study

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold

A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery

Study of 0416 Ointment in the Treatment of Atopic Dermatitis

Comparison of a Daily Disposable Multifocal Contact Lens to a Marketed Product

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

Effectiveness of Magnesium in Addition to Prochlorperazine for the Treatment of Migraines

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease

A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects

Trial of High-Dose Rifampin in Patients With TB

Randomized Evaluation of Natural Extract for Menopausal Wellness (RENEW)

Envarsus XR in Lung Transplant

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

Effects of a Novel Food Product Containing Microbiota Accessible Carbohydrates on the Human Microbiome

Efficacy Study of AlphaBRAIN Administered Orally

Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access

Phase I Study of VLX-1005 in Healthy Subjects

Safety and Efficacy Study of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel to Treat Rosacea

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy